569 results on '"Conti, Rena"'
Search Results
2. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act
3. The estimated annual financial impact of gene therapy in the United States
4. Access to affordable medicines: obligations of universities and academic medical centers
5. Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery
6. Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015–2019
7. Health insurance among survivors of childhood cancer following affordable care act implementation
8. Disparities in clinical trial enrollment at a Canadian comprehensive cancer center: A 15‐year retrospective study
9. Buprenorphine Dispensing after Elimination of the Waiver Requirement
10. Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists
11. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021
12. Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
13. Association Between Cost Sharing and Naloxone Prescription Dispensing.
14. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer‐Reviewed Literature.
15. Stockpiling at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices
16. Job lock among survivors of childhood cancer and their spouses post Affordable Care Act implementation: A Childhood Cancer Survivor Study brief report
17. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad
18. Financial hardship among siblings of long‐term survivors of childhood cancer: A Childhood Cancer Survivor Study report.
19. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
20. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
21. Out-of-Pocket Spending for Deliveries and Newborn Hospitalizations Among the Privately Insured
22. Sensitivity of Psychosocial Distress Screening to Identify Cancer Patients at Risk for Financial Hardship During Care Delivery
23. Minimum Travel Distance Among Publicly Insured Infants with Severe Congenital Heart Disease: Potential Impact of In-state Restrictions
24. COVID-19 Vaccines: Moderna And Pfizer-BioNTech Use Varied By Urban, Rural Counties
25. Job lock among survivors of childhood cancer and their spouses post Affordable Care Act implementation: A Childhood Cancer Survivor Study brief report.
26. Relationship between initiation of 340B participation and hospital safety-net engagement
27. The Myth of the Free Market for Pharmaceuticals.
28. Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022
29. Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer
30. Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market
31. Estimating the Financial Impact of Gene Therapy in the U.S.
32. Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU
33. THE ADVANTAGES OF AWARDING THE FEDERAL GOVERNMENT NEGOTIATING POWER OVER THE PRICES OF PRESCRIPTION DRUGS
34. RESPONSE TO JOYCE AND SOOD
35. Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
36. Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014
37. 21st century pharmacovigilance: efforts, roles, and responsibilities
38. COVID-19 Vaccine–Related Beliefs and Behaviors Among Patients With and Survivors of Hematologic Malignancies
39. Dispensing of Ivermectin From Veterans Administration Pharmacies During the COVID-19 Pandemic
40. Valuing Rare Pediatric Drugs: An Economics Perspective
41. The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications
42. The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration
43. Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?
44. Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data
45. Financial Hardship in Adult Survivors of Childhood Cancer in the Era After Implementation of the Affordable Care Act: A Report From the Childhood Cancer Survivor Study
46. Pricing in the Market for Anticancer Drugs
47. Specialty Drug Prices and Utilization after Loss of US Patent Exclusivity, 2001–2007Specialty Drug Prices and Utilization after Loss of Exclusivity
48. International Reference Pricing in the Context of US Drug Policy
49. Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States
50. Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015–2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.